

AUSPICES

GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo

SIES - Società di Ematologia Sperimentale




4th MEETING ON INNOVATIVE IMMUNOTHERAPIES FOR LYMPHOID MALIGNANCIES

Presidents

Paolo Corradini

Marco Ruella

Pier Luigi Zinzani



MILANO, STARHOTELS ROSA GRAND

January 22-23, 2026

SCIENTIFIC SECRETARIAT

Paolo Corradini

Fondazione IRCCS - Istituto Nazionale dei Tumori
Cattedra di Ematologia
Università degli Studi di Milano
Via Venezian, 1 - 20133 Milano, Italy

Marco Ruella

Perelman Center for Advanced Medicine
Department of Medicine
University of Pennsylvania
3400 Civic Center Blvd - 191004 Philadelphia, PA, USA

Pier Luigi Zinzani

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Istituto di Ematologia “Lorenzo e Ariosto Seràgnoli”
Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale
Università di Bologna
Via Massarenti, 9 - 40138 Bologna, Italy

STEPHEN M.	ANSELL	Rochester, USA
STEFAN K.	BARTA	Philadelphia, USA
RAFET	BASAR	Houston, USA
CATHERINE	BOLLARD	Washington, USA
FRANCESCA	BONIFAZI	Bologna, Italy
MARIA CHIARA	BONINI	Milano, Italy
ELIZABETH	BUDDE	Duarte, USA
CARMELO	CARLO-STELLA	Rozzano-MI, Italy
CRISTIANA	CARNITI	Milano, Italy
MONICA	CASUCCI	Milano, Italy
FABIO	CICERI	Milano, Italy
ADAM D.	COHEN	Philadelphia, USA
PAOLO	CORRADINI	Milano, Italy
ENRICO	DERENZINI	Milano, Italy
LORENZO	FALCHI	New York, USA
FRANCESCA	GAY	Torino, Italy
ALEX F.	HERRERA	Duarte, USA
MICHAEL	HUDECEK	Würzburg, Germany
MARTIN	HUTCHINGS	Copenhagen, Denmark
MICHAEL	JAIN	Tampa, USA
SAAD	KENDERIAN	Rochester, USA
JOHN	KURUVILLA	Toronto, Canada
BRUCE L.	LEVINE	Philadelphia, USA
FREDERICK	LOCKE	Tampa, USA
ENRICO	LUGLI	Pieve Emanuele-MI, Italy
SATTVA S.	NEELAPU	Houston, USA
VINCENZO MARIA	PERRIELLO	Perugia, Italy
CONCETTA	QUINTARELLI	Roma, Italy
CARLOS A.	RAMOS	Houston, USA
KAI	REJESKI	München, Germany
MARCO	RUELLA	Philadelphia, USA
STEPHEN J.	SCHUSTER	Philadelphia, USA
PAOLO	STRATI	Houston, USA
SARAH	TETTAMANTI	Monza-MB, Italy
CATHERINE	THIEBLEMONT	Paris, France
MAX S.	TOPP	Würzburg, Germany
SAAD Z.	USMANI	Charlotte, USA
MICHAEL	WANG	Houston, USA
PIER LUIGI	ZINZANI	Bologna, Italy

09.00 am Welcome and introduction
P. Corradini, M. Ruella, P.L. Zinzani

SESSION I
THE EVOLVING ROLE OF CHECKPOINT INHIBITORS IN LYMPHOMAS
Chairman: **P.L. Zinzani**

09.15 am In Hodgkin lymphoma
A.F. Herrera

09.40 am In non-Hodgkin lymphoma
J. Kuruvilla

10.05 am Mechanisms of resistance to checkpoint inhibitors, novel checkpoints
and novel combinations
S.M. Ansell

10.30 am *Coffee break*

SESSION II
BISPECIFIC T-CELL ENGAGERS IN LYMPHOMA AND MYELOMA
Chairman: **C. Carlo-Stella**

10.45 am Clinical results of bispecific antibodies in aggressive NHL: what's next?
M. Hutchings

11.10 am Clinical results of bispecific antibodies in indolent NHL: what's next?
L. Falchi

11.35 am New bispecifics and... trispecifics
C. Thieblemont

12.00 pm Clinical results in multiple myeloma: BCMA, what's next?
F. Gay

12.25 pm Clinical results in multiple myeloma: GPRC5D, FcRH5 and novel targets
A.D. Cohen

12.50 pm Discussion

01.00 pm *Lunch*

SESSION III
RESISTANCE TO BISPECIFIC T-CELL ENGAGERS

Chairman: **E. Derenzini**

- 02.30 pm In non-Hodgkin lymphomas
E. Budde
- 02.55 pm In multiple myeloma
S.Z. Usmani

SESSION IV
DEBATE

Chairman: **F. Locke**

- 03.20 pm Is there a role for allogeneic transplant after bispecifics and CAR-T in NHL?
Yes C. Bollard
No S.J. Schuster
- 03.40 pm Panel discussion

SESSION V
IMMUNOTHERAPY “MADE IN ITALY”

Chairmen: **M.C. Bonini, M. Ruella**

- 03.50 pm Humanitas: recent advances in modulation of T-cell function against cancer
E. Lugli
- 04.10 pm Innovative immunotherapies at Seràgnoli Insitute - University of Bologna
F. Bonifazi
- 04.30 pm IEO’s latest contributions in cellular therapies
E. Derenzini
- 04.50 pm San Raffaele: cutting-edge CAR-T developments
M. Casucci
- 05.10 pm *Coffee break*
- 05.25 pm New efforts at Ospedale Bambin Gesù Roma
C. Quintarelli
- 05.45 pm New efforts in Bergamo and Monza
S. Tettamanti
- 06.05 pm New targets and CAR-T for lymphoma developed at the University of Perugia
V.M. Perriello
- 06.25 pm Clinical-translational results from the Istituto Nazionale Tumori in Milano
C. Carniti

SESSION VI
CLINICAL UPDATES IN CAR-T THERAPIES

Chairmen: **P. Corradini, M. Wang**

- 08.30 am Clinical results CAR-T for DLBCL: what’s next?
S.J. Schuster
- 08.55 am Clinical results CAR-T for mantle cell lymphoma: what’s next?
M. Wang
- 09.20 am Clinical results CAR-T for follicular lymphoma: what’s next?
P. Strati
- 09.45 am Clinical results CAR-T for T-cell lymphomas: are we catching up?
S.K. Barta
- 10.10 am Clinical results CAR-T for Hodgkin lymphoma: are we catching up?
C.A. Ramos
- 10.35 am *Coffee break*

SESSION VII
ADVANCES IN CELL THERAPIES

Chairman: **F. Ciceri**

- 10.50 am New effector cells for immunotherapy: NK, NKT, gd T-cells and macrophages
R. Basar
- 11.15 am In vivo CAR-T therapies
B.L. Levine

SESSION VIII
T-CELL BASED THERAPY TOXICITIES

Chairman: **K. Rejeski**

- 11.40 am CAR-T toxicities in NHL and MM: non-relapse mortality, infections, secondary cancers and delayed neurotoxicities
K. Rejeski
- 12.05 pm Bispecific antibodies’ toxicities in NHL and MM
M.S. Topp
- 12.30 pm Strategies to reduce early and late CAR-T toxicities
S. Kenderian
- 12.55 pm *Lunch*

SESSION IX
CAR-T RESISTANCE AND NOVEL OPPORTUNITIES

Chairman: **S.S. Neelapu**

02.00 pm	Resistance mechanisms of CAR-T cells in lymphoma: clinical evidence F. Locke
02.25 pm	Laboratory-based mechanisms of CAR-T resistance M. Hudecek
02.50 pm	Patient selection, bridging therapy and lymphodepletion techniques M. Jain
03.15 pm	Novel CAR-T target for T/NK cell malignancies S.S. Neelapu
03.40 pm	Microbiome, diet and host factors: how do they affect T-cell immunotherapies M. Ruella
04.05 pm	Conclusions and arrivederci!

General information

Meeting venue
Starhotels Rosa Grand
Piazza Fontana, 3 - 20122 Milano
Phone: +39 02 88311

Official language
English

Registration fee
Registration is free and available at www.ercongressi.it - section "I nostri congressi/anno 2026"

Badge and certificate of attendance
All registered participants, speakers and sponsors will be given a badge which they must wear to be admitted to the scientific sessions. A certificate of attendance will be given to all participants at the end of the meeting.

Italian CME credits
An Italian CME application has been submitted as follows:
• Provider SIE - Società Italiana di Ematologia: ID 1298 - 467319
• No. 4,2 CME credits for Physicians (disciplines: allergy and clinical immunology; dermatology and venereology; hematology; internal medicine; oncology; pathological anatomy; clinical biochemistry; clinical pathology), Biologists and Chemists (disciplines: public chemist of the national health service; local chemist; chemist in other sectors).
• Educational objective: "guidelines - protocols - procedures".

European CME credits
The program of the meeting has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 13,5 CME credits for Physicians, Biologists and Chemists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

Changes
Parts of the program may be changed without notice.

Slides
Slides must be in English. Slides should be handed to the slide center two hours before the beginning of the session.

With the unrestricted educational grant of



Johnson & Johnson



SIE PERMANENT SECRETARIAT

Via De' Poeti, 1/7 - 40124 Bologna, Italy

Tel. +39 051 6390906

segreteria@sie@ercongressi.it

www.siematologia.it



ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy

Tel. +39 051 4210559

ercongressi@ercongressi.it

www.ercongressi.it

ER Congressi

